Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Compugen Ltd (NQ: CGEN )

1.765 -0.065 (-3.55%)
Streaming Delayed Price Updated: 12:42 PM EDT, Sep 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Compugen Ltd

< Previous 1 2 3 4 5 Next >
CGEN Stock Earnings: Compugen Beats EPS, Beats Revenue for Q2 2024
CGEN stock results show that Compugen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
CGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024
CGEN stock results show that Compugen missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023
CGEN stock results show that Compugen missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
7 Speculative Stocks to Double Your Money THIS Year
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around. 
Via InvestorPlace
Crude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares Plunge
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday. The Dow traded up 0.53% to 37,505.25 while the NASDAQ rose 0.51% to 14,980.71. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
5 Analysts Have This to Say About Compugen
Via Benzinga
Compugen Earnings Preview
Via Benzinga
Expert Ratings for Compugen
Via Benzinga
Compugen: Q1 Earnings Insights
Via Benzinga
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
Earnings Preview For Compugen
Via Benzinga
Earnings Preview: Compugen
Via Benzinga
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
Dow Jumps 150 Points; FactSet Shares Rise After Q1 Results
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.46% to 37,476.21 while the NASDAQ rose 0.41% to 14,966.74. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Compugen Ltd. (NASDAQ: CGEN) is One of Tuesday Morning’s Most Active Stocks
Via Investor Brand Network
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the  
Via Benzinga
Why Are Stocks Up Today?
Stocks are up today and investors wondering why will want to keep reading as we have a breakdown of the market's rally on Tuesday! 
Via InvestorPlace
Why Is Compugen (CGEN) Stock Up 189% Today?
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences. 
Via InvestorPlace
US Stocks Higher; Accenture Issues Weak Sales Outlook
U.S. stocks traded higher this morning, with the Dow Jones index gaining around more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.17% to 37,369.84 while the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning! 
Via InvestorPlace
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
From Gilead Sciences, Inc.
Via Business Wire
7 Promising Penny Stocks With the Potential to Defy Expectations
While market speculation can get extremely dangerous, those who understand the risks may like these high-potential penny stocks. 
Via InvestorPlace
Use Support And Resistance Levels To Avoid Chaos In Your Portfolio
A support line is a price level where a stock historically stops declining. It can be a flat line all at one price, or it can be a trend line that gradually moves in one direction. Here is a closer... 
Via Talk Markets
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN
Via AB Newswire
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Why Compugen Shares Are Up Today
The company released its fourth-quarter and full-year results after the bell Monday. 
Via The Motley Fool
Why Compugen Stock Got Slammed Today
Clinical-stage biotechs are particularly susceptible to shifts in analyst sentiment. 
Via The Motley Fool
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.